Literature DB >> 21262858

Acute effects of donepezil in healthy young adults underline the fractionation of executive functioning.

G E Ginani1, S Tufik, O F A Bueno, M Pradella-Hallinan, J Rusted, S Pompéia.   

Abstract

The cholinergic system is involved in the modulation of both bottom-up and top-down attentional control. Top-down attention engages multiple executive control processes, but few studies have investigated whether all or selective elements of executive functions are modulated by the cholinergic system. To investigate the acute effects of the pro-cholinergic donepezil in young, healthy volunteers on distinct components of executive functions we conducted a double-blind, placebo-controlled, independent-groups design study including 42 young healthy male participants who were randomly assigned to one of three oral treatments: glucose (placebo), donepezil 5 mg or donepezil 7.5 mg. The test battery included measures of different executive components (shifting, updating, inhibition, dual-task performance, planning, access to long-term memory), tasks that evaluated arousal/vigilance/visuomotor performance, as well as functioning of working memory subsidiary systems. Donepezil improved sustained attention, reaction times, dual-task performance and the executive component of digit span. The positive effects in these executive tasks did not correlate with arousal/visuomotor/vigilance measures. Among the various executive domains investigated donepezil selectively increased dual-task performance in a manner that could not be ascribed to improvement in arousal/vigilance/visuomotor performance nor working memory slave systems. Other executive tasks that rely heavily on visuospatial processing may also be modulated by the cholinergic system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262858     DOI: 10.1177/0269881110391832

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

Review 1.  Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.

Authors:  Fabrizio Schifano; Valeria Catalani; Safia Sharif; Flavia Napoletano; John Martin Corkery; Davide Arillotta; Suzanne Fergus; Alessandro Vento; Amira Guirguis
Journal:  Drugs       Date:  2022-04-02       Impact factor: 9.546

2.  Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults.

Authors:  Brian T Harel; Robert H Pietrzak; Peter J Snyder; Paul Maruff
Journal:  Psychopharmacology (Berl)       Date:  2013-04-09       Impact factor: 4.530

3.  A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25-35-impaired mouse cognitive function.

Authors:  Zhengping Zhang; Rong Chen; Wenji An; Chunmei Wang; Gaoyong Liao; Xiaoliang Dong; Aijing Bi; Zhimin Yin; Lan Luo
Journal:  Psychopharmacology (Berl)       Date:  2015-11-11       Impact factor: 4.530

4.  Effects of Donepezil Hydrochloride on Neuronal Response of Pyramidal Neurons of the CA1 Hippocampus in Rat Model of Alzheimer's Disease.

Authors:  Azade Eskandary; Ahmad Ali Moazedi; Hosein Najaph Zade; Mohamad Reza Akhond
Journal:  Basic Clin Neurosci       Date:  2019-03-01

5.  A fractionated analysis of hot and cool self-regulation in cigarette smokers from different socioeconomic backgrounds.

Authors:  Raquel de Luna Antonio; Sabine Pompeia
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

6.  Executive function subcomponents and their relations to everyday functioning in healthy older adults.

Authors:  Courtney McAlister; Maureen Schmitter-Edgecombe
Journal:  J Clin Exp Neuropsychol       Date:  2016-05-20       Impact factor: 2.475

7.  Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study.

Authors:  Roel J T Mocking; C Patrick Pflanz; Abbie Pringle; Elizabeth Parsons; Sarah F McTavish; Phil J Cowen; Catherine J Harmer
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.